{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:10:47Z","timestamp":1760775047992,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012415","name":"Biomedical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012415","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001348","name":"Agency for Science, Technology and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.bmcl.2021.128263","type":"journal-article","created":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:12:21Z","timestamp":1626221541000},"page":"128263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors"],"prefix":"10.1016","volume":"48","author":[{"given":"Subramanyam","family":"Vankadara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun Xuan","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi Yang","family":"See","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li Hong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian Wen","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ratna","family":"Karuna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu Ting","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia Yi","family":"Fong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joma","family":"Joy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.S. Brian","family":"Chia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2021.128263_b0005","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","article-title":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia","volume":"382","author":"Li","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2021.128263_b0010","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2021.128263_b0015","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa030747","article-title":"Identification of a novel coronavirus in patients with severe acute respiratory syndrome","volume":"348","author":"Drosten","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2021.128263_b0020","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1056\/NEJMoa030781","article-title":"A novel coronavirus associated with severe acute respiratory syndrome","volume":"348","author":"Ksiazek","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2021.128263_b0025","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bmcl.2021.128263_b0030","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2021.128263_b0035","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-020-01479-w","article-title":"From SARS and MERS to COVID-19: a brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses","volume":"21","author":"Zhu","year":"2020","journal-title":"Respir Res"},{"key":"10.1016\/j.bmcl.2021.128263_b0040","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","article-title":"The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2","volume":"5","year":"2020","journal-title":"Nat. Microbiol"},{"key":"10.1016\/j.bmcl.2021.128263_b0045","unstructured":"World Health Organization Coronavirus (COVID-19) Dashboard. https:\/\/covid19.who.int; Accessed 3 July 2021."},{"key":"10.1016\/j.bmcl.2021.128263_b0050","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1056\/NEJMp2032369","article-title":"FDA approval of Remdesivir \u2013 a step in the right direction","volume":"383","author":"Rubin","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2021.128263_b0055","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1126\/science.abd0831","article-title":"Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies","volume":"369","author":"Baum","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bmcl.2021.128263_b0060","unstructured":"FDA Press Announcements May 26, 2021. Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-additional-monoclonal-antibody-treatment-covid-19; Accessed 3 July 2021."},{"key":"10.1016\/j.bmcl.2021.128263_b0065","unstructured":"World Health Organization Newsroom. Feature Stories. https:\/\/www.who.int\/news-room\/feature-stories\/detail\/who-recommends-against-the-use-of-remdesivir-in-covid-19-patients. 20 November 2020; Accessed 3 July 2021."},{"key":"10.1016\/j.bmcl.2021.128263_b0070","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/cmdc.202000223","article-title":"Drug development and medicinal chemistry efforts toward SARS-coronavirus and Covid-19 therapeutics","volume":"15","author":"Ghosh","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmcl.2021.128263_b0075","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.drudis.2020.12.005","article-title":"Potential SARS-CoV-2 main protease inhibitors","volume":"26","author":"Banerjee","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.bmcl.2021.128263_b0080","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41422-020-0356-z","article-title":"Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease","volume":"30","author":"Ma","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.bmcl.2021.128263_b0085","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2021.128263_b0090","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1021\/acs.jmedchem.9b01828","article-title":"\u03b1-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: Structure-based design, synthesis, and activity assessment","volume":"63","author":"Zhang","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2021.128263_b0095","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1021\/jm0603926","article-title":"Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor","volume":"49","author":"Yang","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2021.128263_b0100","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.abb4489","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","volume":"368","author":"Dai","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bmcl.2021.128263_b0105","article-title":"Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication","volume":"11","author":"Vuong","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmcl.2021.128263_b0110","doi-asserted-by":"crossref","first-page":"12725","DOI":"10.1021\/acs.jmedchem.0c01063","article-title":"Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19","volume":"63","author":"Hoffman","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2021.128263_b0115","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/cmdc.202000924","article-title":"A quick route to multiple highly potent SARS-CoV-2 main protease inhibitors","volume":"16","author":"Yang","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmcl.2021.128263_b0120","unstructured":"Botyanszki J, Catalano JG, Chong PY, et al. Compounds that inhibit 3C and 3CL proteases and methods of use thereof. WO2018042343A2."},{"key":"10.1016\/j.bmcl.2021.128263_b0125","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1021\/acsnano.0c07383","article-title":"Uncovering flexible active site conformations of SARS-CoV-2 3CL proteases through protease pharmacophore clusters and COVID-19 drug repurposing","volume":"15","author":"Pathak","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.bmcl.2021.128263_b0130","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.bmc.2012.11.017","article-title":"Design and synthesis of new tripeptide-type SARS-CoV 3CL protease inhibitors containing an electrophilic arylketone moiety","volume":"21","author":"Konno","year":"2013","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2021.128263_b0135","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ejmech.2013.05.005","article-title":"Design, synthesis, and biological evaluation of novel dipeptide-type SARS-CoV 3CL protease inhibitors: Structure-activity relationship study","volume":"65","author":"Thanigaimalai","year":"2013","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2021.128263_b0140","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nrd4050","article-title":"Novel therapies for hepatitis C \u2013 one pill fits all?","volume":"12","author":"Manns","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmcl.2021.128263_b0145","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1021\/acsmedchemlett.0c00521","article-title":"Identification of 14 known drugs as inhibitors of the main protease of SARS-CoV-2","volume":"11","author":"Ghahremanpour","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2021.128263_b0150","doi-asserted-by":"crossref","first-page":"11754","DOI":"10.1128\/JVI.01348-12","article-title":"Broad-spectrum antivirals against 3C or 3C-like proteases of Picornaviruses, Noroviruses, and Coronaviruses","volume":"86","author":"Kim","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.bmcl.2021.128263_b0155","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1002\/cmdc.202000921","article-title":"Action of dipeptidyl peptidase-4 inhibitors on SARS-CoV-2 main protease","volume":"16","author":"Nar","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmcl.2021.128263_b0160","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0022-2836(05)80360-2","article-title":"Basic local alignment search tool","volume":"215","author":"Altschul","year":"1990","journal-title":"J Mol Biol"},{"key":"10.1016\/j.bmcl.2021.128263_b0165","doi-asserted-by":"crossref","first-page":"10955","DOI":"10.1021\/acs.jmedchem.9b00875","article-title":"Metabolism by aldehyde oxidase: drug design and complementary approaches to challenges in drug discovery","volume":"62","author":"Manevski","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2021.128263_b0170","doi-asserted-by":"crossref","first-page":"14357","DOI":"10.1021\/acs.jmedchem.0c01177","article-title":"Curse or cure? A perspective on the developability of aldehydes as active pharmaceutical ingredients","volume":"63","author":"Gampe","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2021.128263_b0175","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0960-894X(99)00587-9","article-title":"Structure-based design of ketone-containing, tripeptidyl human rhinovirus 3C protease inhibitors","volume":"10","author":"Dragovich","year":"2000","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2021.128263_b0180","doi-asserted-by":"crossref","unstructured":"Bradshaw TD, Stevens MFG, Westwell AD. The discovery of the potent and selective antitumour agent 2-(4-Amino-3-methylphenyl)benzothiazole (DF 203) and related compounds. Curr. Med. Chem. 2001;8:203\u2212210. doi: 10.2174\/0929867013373714.","DOI":"10.2174\/0929867013373714"},{"key":"10.1016\/j.bmcl.2021.128263_b0185","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3109\/14756366.2012.720572","article-title":"Medicinal significance of benzothiazole scaffold: an insight view","volume":"28","author":"Sharma","year":"2013","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.bmcl.2021.128263_b0190","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1021\/jm980068d","article-title":"Structure-based design, synthesis, and biological evaluation of irreversible human Rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies","volume":"41","author":"Dragovich","year":"1998","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2021.128263_b0195","doi-asserted-by":"crossref","first-page":"11000","DOI":"10.1073\/pnas.96.20.11000","article-title":"Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes","volume":"96","author":"Matthews","year":"1999","journal-title":"PNAS"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X2100490X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X2100490X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:45:12Z","timestamp":1760773512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X2100490X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":39,"alternative-id":["S0960894X2100490X"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2021.128263","relation":{},"ISSN":["0960-894X"],"issn-type":[{"type":"print","value":"0960-894X"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2021.128263","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"128263"}}